Cutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products.

ABSTRACT:

Objective

Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig^® treatment offered a tolerable and safe alternative treatment for immunodeficient patients.

Methods

A one-year prospective cohort study was conducted at a single center in Ottawa, Canada. Adult immunodeficient patients who reported previous intolerability, adverse events, or other difficulty to other 20% SCIG product(s) were recruited to start on 16.5% Cutaquig^®. Treatment tolerability, safety, and quality of life were observed and described.

Results

Seven out of ten patients tolerated Cutaquig^®. There were no serious or severe adverse events

SUBMITTER: Brownlee S 

PROVIDER: S-EPMC9680362 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature